home / stock / nonof / nonof articles
Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart dise...
Danish biotech company Zealand Pharma A/S (OTC:ZLDPF) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial...
Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over...
New side effects of the ‘miracle’ weight loss drug Ozempic are emerging, causing concern among patients and healthcare profes...
The family of a man who died by suicide is seeking a warning label on the ‘miracle’ weight loss drug Ozempic, claiming it contributed t...
News, Short Squeeze, Breakout and More Instantly...
Novo-Nordisk A/S Company Name:
NONOF Stock Symbol:
OTCMKTS Market:
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing . Aspect to receive 75 million US dollars in initial payments and u...
New York City, NY: May 06, 2020 – Published via (Wired Release):- “Market.us presents a new report titled Alkyl Benzyl Dimethyl Ammonium Chloride Market: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and information...